News Releases Year None202320222021 May 18, 2023 YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 May 16, 2023 YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan April 18, 2023 YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023 March 27, 2023 YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study March 16, 2023 YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ March 14, 2023 YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION February 8, 2023 SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION Print Page Email Alerts RSS Feeds Contact IR
Year None202320222021 May 18, 2023 YS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023 May 16, 2023 YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in Pakistan April 18, 2023 YS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023 March 27, 2023 YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical Study March 16, 2023 YS BIOPHARMA TO RING THE OPENING BELL AND DEBUT ON NASDAQ March 14, 2023 YS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATION February 8, 2023 SUMMIT HEALTHCARE ACQUISITION CORP. AND YS BIOPHARMA ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT AND EXTRAORDINARY GENERAL MEETING DATE FOR PROPOSED BUSINESS COMBINATION